Literature DB >> 9922221

Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells.

M Fuhrmann1, H U Jahn, J Seybold, C Neurohr, P J Barnes, S Hippenstiel, H J Kraemer, N Suttorp.   

Abstract

Epithelial cells actively participate in inflammatory airway disease by liberating mediators such as arachidonate metabolites and cytokines. Inhibition of phosphodiesterases (PDEs) may be a useful anti-inflammatory approach. The PDE isoenzyme pattern and the effects of PDE inhibition on mediator generation were analyzed in primary cultures of human and porcine airway epithelial cells (AEC) and in the bronchial epithelial cell line BEAS-2B. PDE4 and PDE5 were detected in lysates of all cell types studied. In primary cultures of human AEC, the PDE4 variants PDE4A5, PDE4C1, PDE4D2, and PDE4D3 were identified by polymerase chain reaction analysis. Evidence of the recently described PDE7 was obtained by rolipram- insensitive cyclic adenosine monophosphate (cAMP) degradation, and its presence was verified by the demonstration of PDE7 messenger RNA. Primary cultures of human airway epithelium also expressed PDE1. Enhanced epithelial cAMP levels, induced by forskolin and PDE4 inhibition, increased formation of prostaglandin E2 (PGE2), but not of interleukin (IL)-8 or 15-hydroxyeicosatetraenoic acid (15-HETE) in airway epithelial cells. Increased cyclic guanosine monophosphate levels in these cells provoked by sodium nitroprusside and the PDE5 inhibitor zaprinast reduced the PGE2 synthesis, whereas 15-HETE and IL-8 formation were unchanged. The data suggest that PDE isoenzymes are important in airway inflammation and that PDE inhibitors exert anti-inflammatory effects by acting on AEC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9922221     DOI: 10.1165/ajrcmb.20.2.3140

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  21 in total

1.  Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D.

Authors:  G Hansen; S Jin; D T Umetsu; M Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 2.  PDE4 inhibitors: current status.

Authors:  D Spina
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

3.  The tyrosine kinase inhibitor genistein increases basal cAMP and potentiates forskolin-induced cAMP accumulation in A549 human airway epithelial cells.

Authors:  Karin M Burvall; Lena Palmberg; Kjell Larsson
Journal:  Mol Cell Biochem       Date:  2002-11       Impact factor: 3.396

Review 4.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 5.  Clinical pharmacology of Cilomilast.

Authors:  Geoff Down; Sarah Siederer; Sam Lim; Peter Daley-Yates
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  A low [Ca2+]i-induced enhancement of cAMP-activated ciliary beating by PDE1A inhibition in mouse airway cilia.

Authors:  Haruka Kogiso; Shigekuni Hosogi; Yukiko Ikeuchi; Saori Tanaka; Chikao Shimamoto; Hitoshi Matsumura; Takashi Nakano; Koh-Ichi Sano; Toshio Inui; Yoshinori Marunaka; Takashi Nakahari
Journal:  Pflugers Arch       Date:  2017-05-05       Impact factor: 3.657

7.  Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.

Authors:  M Profita; G Chiappara; F Mirabella; R Di Giorgi; L Chimenti; G Costanzo; L Riccobono; V Bellia; J Bousquet; A M Vignola
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

8.  Streptococcus pneumoniae-induced caspase 6-dependent apoptosis in lung epithelium.

Authors:  Bernd Schmeck; Ralph Gross; Phillipe Dje N'Guessan; Andreas C Hocke; Sven Hammerschmidt; Tim J Mitchell; Simone Rosseau; Norbert Suttorp; Stefan Hippenstiel
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 9.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 10.  PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.

Authors:  Victoria Boswell-Smith; Domenico Spina
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.